Both type 1 and type 2 diabetic patients have an increased incidence of ischemic heart disease and congestive heart failure. Cardiovascular disease accounts for up to 80% of the excess mortality in patients with type 2 diabetes. The burden of cardiovascular disease is especially pronounced in diabetic women. Factors that underlie diabetic heart disease include multiple vessel coronary artery disease, long-standing hypertension, metabolic derangements such as hyperglycemia and dyslipidemia, microvascular disease, and autonomic neuropathy. There is also increased sudden death associated with diabetes, which is due, in part, to the underlying autonomic neuropathy. This article reviews diabetic cardiac disease, with an emphasis on type 2 diabetes.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
References and Recommended Reading
Haffner SM, Lehto S, Rönnemaa T, et al.: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infraction. N Engl J Med 1998, 339:229–234.
Haffner SM: Coronary heart disease in patients with diabetes. N Engl J Med 2000, 342:1040–1042.
Sowers JR, Epstein M, Frolich ED: Diabetes, hypertension and cardiovascular disease: an update. Hypertension 2001, 37:1053–1059.
Manson JE, Colditz GA, Stampfer MJ, et al.: A prospective study of maturity-onset diabetes mellitus and risk of coronary heart disease and stroke in women. Arch Intern Med 1991, 151:1141–1147.
Gustafsson I, Hildebrundt P: Early failure of the diabetic heart. Diabetes Care 2001, 24:3–4.
Shindler DM, Kostis JB, Yusuf S, et al.: Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry. Am J Cardiol 1996, 77:1017–1020.
Sowers JR: Diabetes mellitus and cardiovascular disease in women. Arch Intern Med 1998, 158:617–621.
Grundy SM, Pasternak R, Greenland P, et al.: AHA/ACC scientific statement: assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. J Am Coll Cardiol 1999, 34:1348–1359.
McFarlane SI, Banerji M, Sowers JR: Insulin resistance and cardiovascular disease. J Clin Endocrinol Metab 2001, 86:713–718.
Stamler J, Vaccaro O, Neaton JD, Wentworth D: Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993, 16:434–444.
McFarlane SI, Jacober SJ, Winer N, Sowers JR: Control of cardiovascular risk factors in patients with diabetes and hypertension at urban academic medical centers. Diabetes Care 2002, 25:718–723.
Rodriguez BL, Lau N, Burchfiel CM, et al.: Glucose intolerance and 23-year risk of coronary heart disease and total mortality. The Honolulu Heart Program. Diabetes Care 1999, 22:1262–1265.
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS. UK Prospective Diabetes Study Group [no authors listed]. BMJ 1998, 317:703–713.
Assman G, Cullen P, Schulte H: Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Münster (PROCAM) study. Circulation 2002, 105:310–315.
Intensive blood-glucose controls with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group [no authors listed]. Lancet 1998. 325:837–853.
Standl E, Schnell O: A new look at the heart in diabetes mellitus: from ailing to failing. Diabetologia 2000, 43:1455–1469.
Malmberg K, Ryden L, Efendic S, et al.: Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol 1995, 26:57–65.
Risk factors for coronary artery disease in non-insulin dependent diabetes (UKPDS23). UKPDS (United Kingdom Prospective Diabetes Study) Group [no authors listed]. BMJ 1998, 316:823–828.
Schannwell CM, Scheppenheim M, Perings S, et al.: Left ventricular diastolic dysfunction as an early manifestation of diabetic cardiomyopathy. Cardiology 2002, 98:33–39.
Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF) [no authors listed]. Lancet 1999, 353:2001–2007.
Packer M, Poole-Wilson PA, Armstrong PW, et al.: Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation 1999, 100:2312–2318.
Kitzman DW, Gardin JM, Gottdiener JS, et al.: Cardiovascular Health Study: importance of heart failure with preserved systolic function in patients Š 65 years of age. Am J Cardiol 2001, 87:413–419.
Nilsson G: Diabetes prevalence in acute MI patients. Cardiol Rev 2002, 19:23–25.
Grundy SM, Howard B, Smith S Jr, et al.: Prevention Conference VI: Diabetes and Cardiovascular Disease. executive summary: conference proceeding for healthcare professionals from a special writing group of the American Heart Association. Circulation 2002, 105:2231–2239.
Henry P, Thomas F, Benetos A, Guize L: Impaired fasting glucose, blood pressure and cardiovascular mortality. Hypertension 2002, 40:458–463.
Sowers JR, Reed J: 1999 Clinical advisory treatment of hypertension and diabetes. J Clin Hypertens 2000, 2:132–133.
Hansson L, Zanchetti A, Carruthers SG, et al.: Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 1998, 351:1755–1762.
Tuomilehto J, Rastenyte D, Birkenhager WH, et al.: Effects of calcium channel blockers in older patients with diabetes and systolic hypertension. NEngl J Med 1999, 340:677–684.
Fagan TC, Sowers J: Type 2 diabetes mellitus: greater cardiovascular risks and greater benefits of therapy. Arch Intern Med 1999, 24;159:1033–1034.
Niskanen L, Hedner T, Hansson L, et al.: Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/beta-blocker-based treatment regimen: a subanalysis of the Captopril Prevention Project. Diabetes Care 2001, 24:2091–2096.
Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes: results of the HOPE study and Micro-HOPE substudy. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators [no authors listed]. Lancet 2000, 355:253–259.
Gall MA, Borch-Johnson K, Hougaard P, et al.: Albuminuria and poor glycemic control predict mortality in NIDDM. Diabetes 1995, 44:1303–1309.
Wei M, Gaskell SP, Haffner SM, Stern MP: Effects of diabetes and level of glycemia on all-cause and cardiovascular mortality. The San Antonio Heart Study. Diabetes Care 1998, 21:1167–1172.
Sniderman AD, Scantlebury T, Cianflone K: Hypertriglyceridemic hyperapoB: the unappreciated atherogenic dyslipoproteinemia in type 2 diabetes mellitus. Ann Intern Med 2001, 135:447–459.
Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. LIPID (Long-Term Intervention with Provastatin in Ischemic Disease) Study Group [no authors listed]. N Engl J Med 1998, 339:1349–1357.
McFarlane SI, Muniyappa R, Francisco R, Sowers JR: Pleiotropic effects of statins: lipid reduction and beyond. J Clin Endocrinol Metab 2002, 87:1451–1458.
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. MRC/BHF Heart Protection Study Collaborative Group [no authors listed]. Lancet 2002, 360:7–22.
Haffner SM, Alexander CM, Cook TJ, et al.: Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analysis in the Scandinavian Simvastatin Survival Study. Arch Intern Med 1999, 159:2661–2667.
Sacks FM, Tonkin AM, Cranen T, et al.: Coronary heart disease in patients with low LDL-cholesterol: benefits of pravastatin in diabetes and enhanced role for HDL-cholesterol and triglycerides as risk factors. Circulation 2002, 105:1424–1428.
Pradhan AD, Ridker PM: Do atherosclerosis and type 2 diabetes share a common inflammatory basis? Eur Heart J 2002, 195:1–4.
Sowers JR: Hypertension, angiotensin II, and oxidative stress. N Engl J Med 2002, 346:1999–2001.
Hak AE, Stehouwer CD, Bots ML, et al.: Associations of C-reactive protein with measures of obesity, insulin resistance, and subclinical atherosclerosis in healthy, middle-aged women. Atheroscler Thromb Vasc Biol 1999, 19:1986–1991.
Natarjan R, Gerrity RG, Gu J-L, et al.: Role of 12-lipoxygenase and oxidant stress in hyperglycemia-induced acceleration of atherosclerosis in a diabetic pig model. Diabetologia 2002, 45:125–133.
Aspirin therapy in diabetes (position statement). American Diabetes Association [no authors listed]. Diabetes Care 2000, 23(suppl 1):S61–S62.
Francis GS: Diabetic cardiomyopathy: fact or fiction? Heart 2001, 89:247–248.
Way KJ, Katai N, King GL: Protein kinase C and the development of diabetic vascular complications. Diabet Med 2001, 18:945–959.
Giles TD, Ouyang J, Kerut EK, et al.: Changes in protein kinase C in early cardiomyopathy and in gracilis muscle in the BB/Wor diabetic rat. Am J Physiol Circ Physiol 1998, 43:H295-H307.
Duttla K, Podolin DA, Davidson MB, Davidoff AJ. Cardiomyocyte dysfunction in sucrose-fed rats is associated with insulin resistance. Diabetes 2001, 50:1186–1192.
Cai L, Kang YJ: Oxidative stress and diabetic cardiomyopathy: a brief review. Cardiovasc Toxicol 2001, 1:181–193. A survey of the current understanding of oxidative injury on the heart and its clinical implications.
Duraisamy Y, Slevin M, Smith N, et al.: Effect of glycation on basic fibroblast growth factor induced angiogenesis and activation of associated signal transduction pathways in vascular endothelial cells: possible relevance to wound healing in diabetes. Angiogenesis 2001, 4:277–288.
Huynh NT, Tayek JA: Oral arginine reduces systemic blood pressure in type 2 diabetes: its potential role in nitric oxide generation. J Am Coll Nutr 2002, 21:422–427.
Cardillo C, Campia U, Bryant MB, Panza JA:. Increased activity of endogenous endothelin in patients with type II diabetes mellitus. Circulation 2002, 106:1783–1787.
Schneider JG, Tilly N, Hierl T, et al.: Elevated plasma endothelin-1 levels in diabetes mellitus. Am J Hypertens 2002, 15:967–972.
Aronson D: Potential role of advanced glycosylation end products in promoting restenosis in diabetes and renal failure. Med Hypotheses 2002, 59:297–301.
Choi KM, Zhong Y, Hoit BD, et al.: Defective intracellular Ca2+ signaling contributes to cardiomyopathy in type 1 diabetic rats. Am J Physiol Circ Physiol 2002, 283:H1398-H1408. Data from this study reveal contractile dysfunction in diabetic rats based on the reduction of the amplitude and kinetics of Ca(2+)(i) transients.
Ren J, Bode AM: Altered cardiac excitation-contraction coupling in ventricular myocytes from spontaneously diabetic BB rats. Am J Physiol Heart Circ Physiol 2000, 279:H238-H244.
Grundy SM, Benjamin IJ, Burke GL, et al.: Diabetes and cardiovascular disease. Circulation 1999, 100:1134–1146.
Sowers JR, Lester MA: Diabetes and cardiovascular disease. Diabetes Care 1999, 22(suppl 3):C14-C20.
Meier-Ewert HK, Nesto RW: Targeting the use of glycoprotein IIb/IIIa antagonists: the diabetic patient. Rev Cardiovasc Med 2002, 3(suppl 1):S20-S27.
Ren J, Samson WK, Sowers JR: Insulin-like growth factor 1 as a cardiac hormone: physiological and pathophysiological implications in heart disease. J Moll Cell Cardiol 1999, 31:2049–2061.
Peruzzi F, Prisco M, Dews M, et al.: Multiple signaling pathways of the IGF-I receptor in protection from apoptosis. Moll Cell Biol 1999, 19:7203–7215.
Frustaci A, Kajstura J, Chimenti C, et al.: Myocardial cell death in human diabetes. Circ Res 2000, 87:1123–1132.
Fiordaliso F, Li B, Latini R, et al.: Myocyte death in streptozotocin-induced diabetes in rats in angiotensin II-dependent. Lab Invest 2000, 80:513–527.
Neumann S, Huse K, Semrau R, et al.: Aldosterone and d-glucose stimulate the proliferation of human cardiac myofibroblasts in vitro. Hypertension 2002, 39:756–760.
Seven-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI) by treatment and diabetic. The BARI Investigators [no authors listed]. J Am Coll Cardiol 2000, 35:1122–1129.The original results of 1829 patients with multivessel disease followed for more than 7 years.
Frye RL, Bell MR, Schaff HV, et al.: The role of PCI and CABG in the management of coronary artery disease in patients with diabetes. Curr Diabetes Rep 2002, 2:16–20. A thorough analysis of the outcome of major invasive procedures in diabetic patients.
Kurbaan AS, Bowker TJ, Ilsley CD, et al.: Difference in the mortality of the CABRI diabetic and nondiabetic populations and its relation to coronary artery disease and the revascularization mode. Am J Coll Cardiol 2001, 87:947–950. Original data of the CABRI study revealing a 4-year doubling of mortality in diabetic patients as an entire population and in those randomized to PTCA, but a nonsignificant difference in those randomized to CABG.
Kurbaan AS, Bowker TJ, Ilsley CJ, et al.: The effect of adjusting for baseline risk factors and post revascularization coronary disease on comparisons between coronary angioplasty and bypass surgery. IntJ Cardiol 2001, 77:207–214.
Niles NW, McGrath P, Malenka D, et al.: Survival of patients with diabetes and multivessel coronary artery disease after surgical or percutaneous coronary revascularization: Results of a large regional prospective study. Northern New England Cardiovascular Disease Study Group. J Am Coll Cardiol 2001, 37:1008–1015.
Zheng JZ, Croft JB, Giles WH, Mensah GA: Sudden cardiac death in the United States, 1989 to 1998. Circulation 2001, 104:2158–2163.
Solini A, Passaro A, D'Elia K, et al.: The relationship of plasma glucose and electrocardiographic parameters in elderly women with different degrees of glucose intolerance. Aging 2000, 12:249–255. The authors found ECG changes consistent with diabetic cardiomyopathy even in patients considered to have a normal glucose tolerance, but with areas under curve with an oral glucose tolerance test higher than median value.
Airaksinen KEJ: Silent coronary artery in diabetes—a feature of autonomic neuropathy or accelerated atherosclerosis? Diabetologia 2001, 44:259–266. A detailed review of recent data concerning asymptomatic ischemia and MI in diabetic patients and its relationship to autonomic neuropathy.
Schnell O, Hammer K, Muhr-Becker D, et al.: Cardiac sympathetic dysinnervation in type 2 diabetes mellitus with and without ECG-based cardiac autonomic neuropathy. J Diabetes Complications 2002, 16:220–227.
Valensi PE, Johnson NB, Maison-Blanche P, et al.: Influence of cardiac autonomic neuropathy on heart rate dependence of ventricular repolarization in diabetic patients. Diabetes Care 2002, 25:918–923.
Ren J, Sowers JR, Walsh MF, Brown RA: Reduced contractile response to insulin and IGF-I in ventricular myocytes from genetically obese Zucker rats. Am J Physiol Circ Physiol 2000, 279:H1708-H1714.
About this article
Cite this article
Blendea, M.C., McFarlane, S.I., Isenovic, E.R. et al. Heart disease in diabetic patients. Curr Diab Rep 3, 223–229 (2003). https://doi.org/10.1007/s11892-003-0068-z
- Diabetic Patient
- Coronary Artery Bypass Graft
- Autonomic Neuropathy
- Diabetic Cardiomyopathy
- United Kingdom Prospective Diabetes Study